As the specialty care global business unit of Sanofi, our work at Sanofi-Genzyme is focused in the areas of rare diseases, rare blood disorders, multiple sclerosis, oncology, and immunology. Each day we continue to advance new therapies, demonstrating our commitment to making a positive impact on the lives of patients around the world. For more than 35 years, we have been a pioneer and innovator in rare genetic diseases. Lysosomal storage disorders (LSDs), a group of extremely rare diseases with high unmet need, are an area of expertise for us, particularly Gaucher, Fabry, ASMD, Pompe and Mucopolysaccharidosis (MPS) I diseases. We are continuing to research and develop new therapies for LSDs while leveraging our expertise to expand our focus to other rare conditions. Our support for patients extends beyond our therapies. We are committed to addressing a significant unmet need that still exists in rare diseases: physician and patient access to tools, knowledge and resources that will lead to timely and appropriate diagnosis.
Role within Screen4Care
Sanofi-Genzyme will have an active participation and contribution to all Work Packages in Screen4Care and figure as Efpia lead on WP3 and as Efpia co-lead on WP4.